FDA eases low‑risk wearables
The U.S. FDA issued new guidance this week saying low‑risk health and fitness wearables (activity trackers, non‑diagnostic apps) will face lighter regulatory scrutiny — expected to speed device releases. But watchdogs warn federal investments and data-sharing initiatives could expose sensitive physiological data to brokers or law enforcement, so privacy remains a major tradeoff. (openpr.com) (reason.com)
The FDA published a finalized “General Wellness: Policy for Low Risk Devices” guidance in January 2026 that sets the Center for Devices and Radiological Health’s compliance policy for low‑risk lifestyle products. (fda.gov) In early January the agency updated both its general‑wellness guidance and its clinical decision‑support (CDS) guidance, and FDA Commissioner Marty Makary said the agency added examples clarifying that non‑invasive estimations of blood pressure, oxygen saturation, blood glucose and heart‑rate variability can qualify as wellness functions when they make no clinical claims. (fiercehealthcare.com) The FDA has also launched the Technology‑Enabled Meaningful Patient Outcomes (TEMPO) pilot, announced Dec. 5, 2025, and tied to CMS’s CMMI ACCESS model; the agency began accepting statements of interest for TEMPO on Jan. 2, 2026 and said the pilot focuses on digital tools for cardio‑kidney‑metabolic, musculoskeletal and behavioral‑health conditions. (fda.gov) (federalregister.gov) Market analysts estimate the wearable medical devices market at roughly $43.6 billion in 2024 with forecasts clustering around $220–230 billion by 2033, underscoring the commercial scale at stake for manufacturers and service partners. (datamintelligence.com) (grandviewresearch.com) Privacy groups and reporters say federal funding and data‑sharing plans heighten risk that physiological streams will be accessible outside clinical contexts: Reason highlighted federal investments could leave physiological data exposed to brokers and police, the ACLU warned in an April 28, 2025 policy paper that cross‑agency data linkage can create centralized dossiers, and Politico reported FBI Director Kash Patel confirmed March 18, 2026 that the bureau purchases commercially available tracking data. (reason.com) (assets.aclu.org) (politico.com) Policy responses are already emerging: Senators Ron Wyden, Sara Jacobs, and colleagues recently introduced legislation aimed at closing the “data broker loophole” and requiring warrants for certain location and browsing records, while the Brennan Center has urged Congress to prohibit government purchases of sensitive brokered data. (wyden.senate.gov) (brennancenter.org)
